Axcella Company Profile

08:09 EDT 21st September 2019 | BioPortfolio

News Articles [20 Associated News Articles listed on BioPortfolio]

Axcella Health nets $66.4mm via IPO

Axcella Health Inc. (therapies addressing dysregulated metabolism) netted $66.4mm in its initial public offering of 3.57mm common shares at $20 each, the low end of its anticipated range.

Axcella to Present at the Wedbush PacGrow Healthcare Conference

Axcella Health (Nasdaq: AXLA), a biotechnology company pioneering the research and development of novel multifactorial interventions to address dysregulated metabolism and support health, today annou...

Ex-Novartis Exec Aradhye Joins Axcella as Chief Development Officer

Shreeram Aradhye has been appointed executive vice president and chief development officer of Axcella Health. Aradhye was most recently chief medical officer and global head of medical affairs for Nov...

Axcella Health Files For U.S. IPO

Axcella IPO: The Expected Enterprise Value Is Not Expensive

Management tracks: Epic, Axcella, KalVista

Flagship-backed Axcella seeking NASDAQ IPO

IPO Update: Axcella Health Readies Plan For $75 Million IPO

Drugs and Medications [0 Results]


PubMed Articles [0 Results]


Clinical Trials [0 Results]


Companies [2 Associated Companies listed on BioPortfolio]

Axcella Health Inc.

Axcella is designing and developing novel endogenous metabolic modulator compositions to safely reprogram metabolic dysregulation. We are transforming the discovery and developmen...


More Information about "Axcella" on BioPortfolio

We have published hundreds of Axcella news stories on BioPortfolio along with dozens of Axcella Clinical Trials and PubMed Articles about Axcella for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Axcella Companies in our database. You can also find out about relevant Axcella Drugs and Medications on this site too.

Quick Search

Corporate Database Quicklinks

Searches Linking to this Company Record